Breathe Well Live Well
|
Letter: No new insight on rise in asthma
The Columbian The Sept. 17 Columbian Life cover story, "Those with asthma know shortness of breath is a serious issue," was correct in its title that asthma sufferers already know what they are dealing with, but offered no new relevant information to the public … |
View full post on asthma – Google News
|
GSK and Theravance file for FF/VI approval in the USA and Europe; Talks with …
The Pharma Letter Asthma (100/25mcg and 200/25mcg): The regular treatment of asthma in adults and adolescents aged 12 years and older, where use of a combination product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate. • COPD (100/25mcg): The … GSK, Theravance seek approvals for FF/VI in US, Europe GSK and Theravance file next-generation Advair in USA, EU |
View full post on asthma – Google News
|
Letter: A way to combat asthma
The State Journal-Register I saw the recent article on asthma and sports and thought my experience may be helpful to others. |
View full post on asthma – Google News
|
Global asthma and COPD drug market to reach nearly $27 billion in …
The Pharma Letter The global asthma and chronic obstructive pulmonary disease (COPD) market was worth $25.102 billion in 2010, and is expected to reach $26.965 billion in … |
View full post on asthma – Google News
|
LETTER: Help an asthmatic breathe easier
Superior Telegram To the Telegram: Asthma is a serious, sometimes life-threatening disease that affects almost 20 million people in the United States. In fact, every day in America: Asthma is a serious, sometimes life-threatening disease that affects almost 20 million … |
View full post on asthma – Google News
|
Letter: May is Asthma Awareness Month
Fond du Lac Reporter May is Asthma Awareness Month. Asthma is a serious, sometimes life-threatening disease and affects almost 20 million people in the United States. Every day in America, 40000 people miss school or work, 30000 people have an asthma attack, … May: Asthma Awareness Month Letter: Help asthma suffers: Keep smoke away |
View full post on asthma – Google News
|
MediciNova shares plunge as asthma drug fails in Ph IIb trial
The Pharma Letter MediciNova intends to design pivotal trial(s) that will include technological and operational improvements and further controls for medications that are not typically used in the treatment of acute exacerbations of asthma and were over-represented in … |
View full post on asthma – Google News
|
Letter: Help asthma suffers: Keep smoke away
Wausau Daily Herald EDITOR: A couple of years ago, my daughter, who has asthma, was exposed to secondhand smoke while at a friend's home. The result was a trip to the doctor's office; nebulizer treatments every three hours around the clock for three days; lost sleep for … |
View full post on asthma – Google News
|
Letter: Help asthma suffers: Keep smoke away
Wausau Daily Herald EDITOR: A couple of years ago, my daughter, who has asthma, was exposed to secondhand smoke while at a friend's home. The result was a trip to the doctor's office; nebulizer treatments every three hours around the clock for three days; lost sleep for … |
View full post on asthma – Google News
 Proactive Investors USA & Canada |
Relovair COPD and asthma filings on track despite more mixed trial results
The Pharma Letter For asthma, the company plans to file for approval in Europe in mid-2012 and will continue discussions with the US Food and Drug Administration on the regulatory requirements for a US asthma indication. GSK is looking to replace its top-selling drug … Relovair on track for filing in mid-2012, says GSK GSK, Theravance Report Mixed Bag of Data for Relovair in COPD, Asthma GSK and Theravance Announce Completion of the Relovair(TM)* Registrational … |
View full post on asthma – Google News